
Apr 15, 2025, 07:21
Enrolling for the ComboMATCH Treatment Trial E5 – ECOG-ACRIN Cancer Research Group
ECOG-ACRIN Cancer Research Group shared a post on X:
“ComboMATCH Treatment Trial E5, led by Kristen Spencer, Perlmutter Cancer Center at NYU Langone Health and Dustin Deming, UW Health – Carbone Cancer Center, is a randomized phase 2 study of sotorasib with or without panitumumab in advanced solid tumours.
Learn more here.”
More posts featuring ECOG-ACRIN Cancer Research Group.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 15, 2025, 07:23
Apr 15, 2025, 07:10
Apr 15, 2025, 07:04
Apr 15, 2025, 04:10
Apr 14, 2025, 19:10